Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety

NCT03439072 is registered in ClinicalTrials.gov with Xeris Pharmaceuticals as lead sponsor.

NCT NCT03439072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03439072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety
Lead sponsor
Xeris Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
January 23, 2018
Completion date
May 3, 2018
Enrollment
81 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

insulin hypoglycemia, severe hypoglycemia, type 1 diabetes mellitus